Publication

Article

CURE

Spring 2010
Volume9
Issue 1

Teens Helping Teens

Author(s):

The Childhood Cancer Foundation in Canada recognized the unique needs of teens with cancer and created Teen Connector, a Facebook-style website.

Since the teenage years already come with a long list of problems and worries, having cancer added to the mix seems like it’d be a living nightmare. The Childhood Cancer Foundation in Canada recognized the unique needs of teens with cancer and created Teen Connector (www.teenconnector.ca), a Facebook-style website.

Social networking sites, like Facebook, have become popular tools for individuals of all backgrounds to provide updates on their lives, share their interests, and keep up with old friends, while making new ones. For cancer patients, social networking has also become a great tool for creating a support group (see “Friends in Need”).

Since its launch last fall, Teen Connector has become a place where young cancer patients and survivors can be inspired and supported by special mentors; build a network of friends; share stories in group discussions and journals; create fundraising events; and get cancer-related information geared toward them. The site also provides games and activities.

“It’s got a lot of traditional social networking features, but there’s a lot that’s catered to someone going through treatment, or in the hospital,” says Lauren Donnelly, an 18-year-old cancer survivor from Ontario, Canada. “A lot of things are specialized to cancer patients.”

Donnelly is one of 12 teen cancer survivors who were key to developing the content, functionality, and style of the Teen Connector website. Donnelly also serves as a Teen Connector mentor, a special category of Teen Connector members who are post-treatment and have gone through training to provide support, advice, and motivation to teens currently progressing through their cancer journey.

“It’s been a really great experience talking to teens—being able to encourage them,” says Donnelly, who was diagnosed with acute lymphoblastic leukemia when she was 15. “It’s something I would have loved to have when I was going through treatment.”

This is what makes Teen Connector so unique; it’s designed specifically for teens on treatment. But teens finished with treatment can find a place for themselves, too. And, Donnelly assures, the registration process is very easy.

“You can be online and talking to others going through a similar experience as you within a few minutes.”

Related Videos
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Related Content